Skip to main content

Advertisement

SpringerLink
Log in

Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

Treatment options for antimuscarinic refractory neurogenic detrusor overactivity (NDO) are botulinum toxin type A injections (BTX-A) and augmentation cystoplasty (AC). We estimated initial and cumulative 5-year costs of these treatments.

Materials and methods

Base case is an individual with antimuscarinic refractory NDO and decreased bladder compliance. Primary analysis is from the health care payor perspective. Model probabilities and ranges were derived from literature and chart review. Reimbursements were derived from the average of insurance carriers. Complication cost calculations were based on standard practice. Decision-analysis model was made with TreeAge Pro Healthcare 2009 Software, Inc. and rolled back for cost calculation. One-way sensitivity analysis was performed on all variables, and two-way sensitivity analyses were based on these results.

Results

Average reimbursement for one BTX-A injection and AC was $2,946.83 and $25,041.53, respectively. BTX-A treatment was less expensive over 5 years, costing $28,065. The model was only sensitive within a reasonable clinical range for Botox durability. BTX-A was more cost-effective over 5 years if the effect lasted for >5.1 months. The model was based on an AC complication rate of 40%. If the PAC complication rate < 14%, AC was cheaper over 5 years. The model was sensitive to surgeons costs of BTX-A ($3,027) and facility costs of BTX-A ($1,004) and AC ($17,100).

Conclusions

This is the first cost analysis of BTX-A and AC. BTX-A is cheaper at durations >5.1 months and AC was cheaper when the cost of BTX-A increases or the AC complication rate dropped below 14%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Herschorn S, Hewitt RJ (1998) Patient perspective of long-term outcome of augmentation cystoplasty for neurogenic bladder. Urology 52:672

    Article  CAS  PubMed  Google Scholar 

  2. Stohrer M, Schurch B, Kramer G et al (1999) Botulinum A-toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: a new alternative to medical and surgical procedures? Neurourol Urodyn 18:401

    Article  Google Scholar 

  3. Reitz A, Stohrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510

    Article  CAS  PubMed  Google Scholar 

  4. Karsenty G, Reitz A, Lindemann G et al (2006) Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 68:1193

    Article  PubMed  Google Scholar 

  5. Apostolidis A, Jacques TS, Freeman A et al (2008) Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 53:1245

    Article  CAS  PubMed  Google Scholar 

  6. Kalsi V, Popat RB, Apostolidis A et al (2006) Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 49:519

    Article  CAS  PubMed  Google Scholar 

  7. Boy S, Seif C, Braun P (2008) Retrospective analysis of treatment outcomes and medical care of patients with neurogenic detrusor overactivity (NDO) receiving BOTOX therapy. Eur Urol Suppl 7:212

    Article  Google Scholar 

  8. Del Popolo G, Li Marzi V, Lombardi G (2004) Efficacy, safety and dosage of English botulinum toxin-A in neurogenic detrusor overactivity. Eur Urol 3:A663

    Google Scholar 

  9. Del Popolo G, Filocamo MT, Li Marzi V et al (2008) Neurogenic detrusor overactivity treated with English botulinum toxin a: 8-year experience of one single centre. Eur Urol 53:1013

    Article  CAS  PubMed  Google Scholar 

  10. Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653

    Article  CAS  PubMed  Google Scholar 

  11. Reitz A, Denys P, Fermanian C et al (2007) Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 52:1729

    Article  PubMed  Google Scholar 

  12. Chenet A, Perrouin-Verbe B, Le Normand L et al (2007) Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity. Ann Readapt Med Phys 50:651

    CAS  PubMed  Google Scholar 

  13. Giannantoni A, Mearini E, Del Zingaro M et al (2009) Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 55:705

    Article  CAS  PubMed  Google Scholar 

  14. Karsenty G, Denys P, Amarenco G et al (2008) Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 53:275

    Article  CAS  PubMed  Google Scholar 

  15. Schurch B, de Seze M, Denys P et al (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196

    Article  CAS  PubMed  Google Scholar 

  16. Giannantoni A, Mearini E, Di Stasi SM et al (2004) New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 56:79

    CAS  PubMed  Google Scholar 

  17. Bagi P, Biering-Sorensen F (2004) Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 38:495

    Article  CAS  PubMed  Google Scholar 

  18. Schurch B, Stohrer M, Kramer G et al (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692

    Article  CAS  PubMed  Google Scholar 

  19. Schulte-Baukloh H, Schobert J, Stolze T et al (2006) Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 25:110

    Article  CAS  PubMed  Google Scholar 

  20. Kalsi V, Apostolidis A, Popat R et al (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49:528

    Article  PubMed  Google Scholar 

  21. Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63:868

    Article  PubMed  Google Scholar 

  22. Klaphajone J, Kitisomprayoonkul W, Sriplakit S (2005) Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehabil 86:2114

    Article  PubMed  Google Scholar 

  23. Kennelly M, Kang J (2003) Botulinum-A toxin injections as a treatment for refractory detrusor hyperreflexia. Top Spinal Cord in J Rehabil 8:46

    Article  Google Scholar 

  24. Pannek J, Gocking K, Bersch U (2009) Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int 104:1246

    Article  CAS  PubMed  Google Scholar 

  25. Freedman ER, Singh G, Donnell SC et al (1994) Combined bladder neck suspension and augmentation cystoplasty for neuropathic incontinence in female patients. Br J Urol 73:621

    Article  CAS  PubMed  Google Scholar 

  26. Blyth B, Ewalt DH, Duckett JW et al (1992) Lithogenic properties of enterocystoplasty. J Urol 148:575

    CAS  PubMed  Google Scholar 

  27. Rink RC (1999) Bladder augmentation. Options, outcomes, future. Urol Clin North Am 26:111

    Article  CAS  PubMed  Google Scholar 

  28. Greenwell TJ, Venn SN, Mundy AR (2001) Augmentation cystoplasty. BJU Int 88:511

    Article  CAS  PubMed  Google Scholar 

  29. Chartier-Kastler EJ, Mongiat-Artus P, Bitker MO et al (2000) Long-term results of augmentation cystoplasty in spinal cord injury patients. Spinal Cord 38:490

    Article  CAS  PubMed  Google Scholar 

  30. Gough DC (2001) Enterocystoplasty. BJU Int 88:739

    Article  CAS  PubMed  Google Scholar 

  31. Zachoval R, Pitha J, Medova E et al (2003) Augmentation cystoplasty in patients with multiple sclerosis. Urol Int 70:21

    Article  PubMed  Google Scholar 

  32. Game X, Castel-Lacanal E, Bentaleb Y et al (2008) Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 53:613

    Article  CAS  PubMed  Google Scholar 

  33. Chancellor MB (2009) Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. Int Urol Nephrol

Download references

Acknowledgments

This research was funded by the Vanderbilt Department of Urologic Surgery and the Institute for Medicine and Public Health. Dr. Roger Dmochowski is a consultant for Allergan. None of the other authors have any relevant disclosures.

Author information

Authors and Affiliations

  1. Department of Urologic Surgery, Vanderbilt University, Nashville, TN, USA

    Priya Padmanabhan, Harriette M. Scarpero, Douglas F. Milam, Roger R. Dmochowski & David F. Penson

Authors
  1. Priya Padmanabhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harriette M. Scarpero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas F. Milam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roger R. Dmochowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David F. Penson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David F. Penson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Padmanabhan, P., Scarpero, H.M., Milam, D.F. et al. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urol 29, 51–57 (2011). https://doi.org/10.1007/s00345-010-0618-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-010-0618-3

Keywords

Search

Navigation